Myelodysplastic Syndrome Treatment Market in U S , Europe, globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
2Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany
3General Surgery Department, Tawam Hospital, SEHA, Al Ain, United Arab Emirates
4Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
5Department of Genetics and Molecular Biology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
6Department of Respiratory Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates
7Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada
8Division of Surgery and Interventional Science, University College London, London, United Kingdom
As one of the current global health conundrums, COVID-19 pandemic caused a dramatic increase of cases exceeding 79 million and 1.7 million deaths worldwide. Severe presentation of COVID-19 is characterized by cytokine storm and chronic inflammation resulting in multi-organ dysfunction. Currently, it is unclear whet
:
The rising prevalence of urea cycle disorders is expected to increase the demand for treatment options for urea cycle disorders (UCD), which is expected to drive the growth of global urea cycle disorders treatment market during the forecast period. According to the Urea Cycle Disorders Consortium (UCDC), a part of the Rare Diseases Clinical Research Network (RDCRN), combined prevalence of urea cycle disorders is around 1 in 30,000 people in the U.S in 2017
Among regions, North America is expected to hold dominant position in the global urea cycle disorders treatment market during the forecast period, owing to key companies focusing on product launches for the treatment of Urea cycle disorders. For instance, in January 2021, Recordati Rare Diseases Inc. received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia.